Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that BRAF p.V600K status confers therapeutic sensitivity to Dabrafenib, Trametinib in patients with Melanoma.
The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the adjuvant treatment of adult and adolescent patients aged 12 years and older with stage III melanoma with a BRAF V600 variant, following complete resection.
This statement is based on a regulatory approval from the European Medicines Agency:
Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage III melanoma with a BRAF V600 mutation, following complete resection.